ChemoMetec

ChemoMetec has expressed interest in acquiring the Belgian company Ovizio Imaging Systems SA and has made an indicative purchase offer. The due diligence process and negotiations for the final share purchase agreement are still underway. If these are completed successfully, ChemoMetec expects to finalize the acquisition in the coming weeks. Ovizio specializes in a cell counter using holographic microscopy, mainly used in bioprocessing and cell and gene therapy. In 2023, Ovizio reported a revenue of EUR 1.4 million. ChemoMetec, established in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements to industries worldwide.

The Annual General Meeting of ChemoMetec A/S took place on 10 October 2024 at Nordsjællands KonferenceCenter. During the meeting, the Board of Directors presented their report on the past year's activities, the annual report for 2023/24 was approved, and the Board and Executive Board were discharged. A dividend of DKK 4 per share was approved. Niels Thestrup, Martin Glensbjerg, Kristine Færch, Betina Hagerup, and Peter Reich were re-elected to the Board of Directors, and Deloitte was re-elected as auditor. The meeting also approved the remuneration policy and report, and authorized the Board to acquire treasury shares. After the meeting, Niels Thestrup and Martin Glensbjerg were re-elected as chairman and deputy chairman, respectively. ChemoMetec A/S specializes in developing instruments for cell counting and other measurements for various industries and is listed on Nasdaq OMX Copenhagen.

ChemoMetec has made an indicative offer to acquire Ovizio Imaging Systems, a Belgian company specializing in cell counting technology using holographic microscopy. The offer has been accepted by Ovizio's owners, and ChemoMetec has three weeks to conduct due diligence. If the results are favorable, ChemoMetec is likely to proceed with the acquisition. Ovizio's cell counter is used in bioprocessing and cell and gene therapy, and its product connects directly to bioreactors for continuous cell analysis. In 2023, Ovizio reported revenue of EUR 1.4 million, mainly from consumables and service contracts. ChemoMetec's management believes the acquisition would complement their technologies in the market for automated and integrated cell counting. The impact on ChemoMetec's financial guidance for 2024/25 is currently uncertain. For more information, contact CEO Martin Helbo Behrens or CFO Kim Nicolajsen. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements to various industries, including pharmaceuticals and biotech.

Announcement No. 275, dated 18 September 2024, informs about the Annual General Meeting of ChemoMetec A/S, scheduled for Thursday, 10 October 2024, at 5:30 p.m. The meeting will take place at Nordsjællands KonferenceCenter, Gydevang 39-41, 3450 Allerød. For additional information, Kim Nicolajsen, CFO, can be contacted at (+45) 48 13 10 20. ChemoMetec A/S, established in 1997 and listed on Nasdaq OMX Copenhagen, develops, manufactures, and markets instruments for cell counting and other measurements for the pharmaceutical, biotech, and agricultural industries globally. More details can be found at www.chemometec.com. An attachment with the AGM agenda is included.

ChemoMetec A/S has announced a notification of transactions related to its shares made by individuals in managerial positions or those closely associated with them, in accordance with Article 19 of EU Regulation no. 596/2014. The specific transactions involving CFO Kim Nicolajsen can be found in the attached PDF document. For more details, contact Kim Nicolajsen at ChemoMetec. ChemoMetec develops, manufactures, and markets instruments for cell counting and other measurements, serving the pharmaceutical, biotech, and agricultural industries globally. The company was founded in 1997 and is listed on Nasdaq OMX Copenhagen. Further information is available on their website.

ChemoMetec's annual report for the fiscal year 2023/24, covering the period from July 1, 2023, to June 30, 2024, indicates a challenging year with an 8% decline in revenue to DKK 407.4 million and a 26% decrease in operating profit (EBITDA) to DKK 186.2 million. The revenue drop was mainly due to a 35% fall in instrument sales, although sales of consumables and services increased by 13%. Despite these challenges, the company successfully initiated the gradual launch of its new XcytoMatic 40 and XcytoMatic 30 instruments. CEO Martin Helbo Behrens expressed a more positive outlook for the future, citing intensified commercial focus, organizational changes, and the upcoming wider launch of new instruments, which are expected to diversify the business and strengthen growth potential. The annual report is available on ChemoMetec’s website. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements, serving the pharmaceutical, biotech, and agricultural industries.

ChemoMetec has approved its annual report for 2023/24 and provided guidance for the 2024/25 financial year. The company expects revenue to be between DKK 435-450 million, up from DKK 407.4 million in 2023/24. EBITDA is projected to be between DKK 216-223 million, compared to DKK 186.2 million in 2023/24. The annual report includes the assumptions used for this guidance. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements to the pharmaceutical, biotech, and agricultural industries. For more information, visit www.chemometec.com.

On July 4, 2024, ChemoMetec A/S announced that BlackRock, Inc. has increased its holding of voting rights in the company to 14.21%, surpassing the 10% threshold as per Section 30 of the Capital Markets Act. This increase was executed through BlackRock Investment Management (UK) Limited on July 3, 2024. ChemoMetec A/S is a company that develops and markets instruments for cell counting and other measurements, primarily serving the pharmaceutical, biotech, and agricultural industries. For more information, contact CEO Martin Helbo Behrens at (+45) 4813 1020 or visit www.chemometec.com.

ChemoMetec announced preliminary revenue figures for the 2023/24 financial year. In the fourth quarter, the company achieved a revenue of DKK 109.2 million, reflecting a 13.5% increase from the same period the previous year. However, the total revenue for 2023/24 was DKK 407.4 million, a 7.9% decrease from the previous year's DKK 442.3 million. This revenue aligns with the latest guidance of DKK 400-415 million provided on 8 May 2024. Sales of XcytoMatic instruments in the fourth quarter amounted to DKK 4.4 million, a 69% increase from the third quarter. The company maintains its previously announced EBITDA guidance of DKK 185-200 million for 2023/24. The detailed annual report will be released on 11 September 2024. ChemoMetec, founded in 1997 and listed on the Nasdaq Copenhagen, develops and markets instruments for cell counting and other measurements, primarily serving the pharmaceutical, biotech, and agricultural industries.

ChemoMetec has announced the appointment of Kim Nicolajsen as the new CFO, effective from 1 July 2024. Nicolajsen, previously CFO at Rohde Nielsen and a state-authorized public accountant, has also worked for KPMG and EY. The current CFO, Niels Høy Nielsen, will resign at the same time Nicolajsen takes over. The executive management of ChemoMetec will be formed by CEO Martin Helbo Behrens and the new CFO Nicolajsen. ChemoMetec, founded in 1997, develops, manufactures and markets cell counting instruments and other measurements for the pharmaceutical, biotech and agricultural industries worldwide.